Materials scientists are once again looking to nature to solve a drug delivery problem. This time, researchers from Harvard have investigated the way in which living tissues bring liquids where they're needed and ultimately secrete them--and they developed a synthetic system that mimics the process.
Two companies with a focus on drug delivery are making a go at an IPO, joining several biotechs that have thrown their hats in the ring in the last few days. Belgian gene therapy specialist Celyad--formerly Cardio3--has priced its offering on the Nasdaq for $100 million, and ADHD formulator Neos Therapeutics filed with the SEC to raise up to $69 million.
Bayer is collaborating with Johns Hopkins University's Wilmer Eye Institute to develop new forms of drug delivery to the back of the eye. Targeted diseases include age-related macular degeneration and diabetic macular edema, which both result in in vision loss.
A PhD candidate at Canada's McMaster University is developing a drug delivery contact lens for glaucoma patients because eye drops are incredibly inefficient and deliver only 5% of the active ingredient they carry to the cornea.
Acorda Therapeutics moved a step closer to collecting the payoff from its $525 million acquisition of Civitas, maker of an inhaled levodopa, in the scramble to deliver an improved formulation of the standard Parkinson's med. The conventional oral formulation suffers from unpredictable absorption in the bloodstream and a wearing-off effect after about 5 years.
UPDATED: Microchips Biotech partners with Teva on wireless drug delivery, announces new CEO, raises $18M in financing
On the heels of Microchips Biotech's $35 million partnership with Teva to apply the company's electronic drug delivery implant for administration over months to years toward at least one disease area, the company announced that Cheryl Blanchard, the former chief scientific officer of Zimmer, will become its new CEO.
Two new studies presented at the annual American Diabetes Association have shown the benefits of the hormone glucagon--used to control the concentration of glucose in the bloodstream--in patients with Type 1 diabetes. One is a nasal powder to treat hypoglycemia in children and the other is an advance in the development of an effective artificial pancreas, finding the addition of glucagon could reduce nighttime hypoglycemia.
A study found that tablets increase compliance among postmenopausal women suffering from vaginal atrophy when compared to cream. Almost 90% of patients who took the cream stopped using it after the first prescription, compared to 58% of patients who were on Novo Nordisk's Vagifem 10 milligram estradiol tablets.
Bolstering recent growth in the research of progesterone-loaded intravaginal rings as contraceptives, the World Health Organization has voiced its approval, adding the delivery method to its 2015 essential medicines list, particularly for postpartum women and with a focus on the developing world.
It's been a busy week on Wall Street for Parkinson's players all over the globe. Finland's Biotie Therapies saw its stock surge upon debut on the Nasdaq, Canada's Cynapsus plans to hit the exchange this week, and Israel's Intec Pharma plans to conduct an IPO shortly.
The Centers for Disease Control and Prevention says that a formulation of Endo's pain med, Opana ER--that's supposed to be difficult to crush--is responsible for an outbreak of HIV in southern Indiana, because the changes made it easier to prepare the drug for more dangerous intravenous or subcutaneous injection.
Oculus Innovative Sciences announced that it has received FDA 510(k) clearance for its Alevicyn SG Antipruritic Spray Gel to treat dermatologic conditions like burning and itching skin, as well as skin irritation, lacerations, abrasions and minor burns.
Researchers from MIT demonstrated that a 3-mm-long microdevice holding up to 16 different drugs and drug combinations can release those drugs when implanted directly in a tumor to then determine the tumor's sensitivity to those therapies.
Materials science is a crucial facet of the drug delivery realm, and researchers in the U.K. and Ireland are rallying to bring attention to the importance of crystallization as an important part of the future of drug development and delivery.
Sebacia, the maker of an investigational microparticle-based therapy for acne that's heated by a hand-held laser, received $8 million in financing, raising its total fundraising haul to more than $40 million.
Cancer immunotherapy specialist OncoSec Medical pulled in $13.6 million in a direct offering, funds the company plans to put toward clinical trials and R&D for its ImmunoPulse platform designed to deliver DNA-based immune-targeting agents.
Braeburn Pharmaceuticals is confident about FDA approval of its Probuphine subdermal implant to treat opioid addiction after its pivotal trial demonstrated it worked at least as well as sublingually administered buprenorphine/naloxone. But an unexpected rejection of the candidate by the FDA in 2013 means the outcome is far from certain.
India's Cipla recently got FDA approval for a pediatric formulation of the combo drug lopinavir/ritonavir to treat HIV/AIDS in the developing world, but not in the U.S., where market exclusivity rules apply.
NeuroVive's candidate for aiding in recovery after severe heart attacks failed to meet its endpoint following a topline analysis.
Scientists at the University of Sheffield are developing antibiotic delivery techniques to solve the problem of infected orthopedic joints, which can lead to deadly diseases like sepsis among bone implant patients.